Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966) announced that the latest research progress of JSKN003 was announced during the 2026 ESMO conference poster presentation. The JSKN003 combination treatment showed outstanding anti-tumor activity in HER2+ GC/GEJ first-line treatment. Among them, Cohort B showed outstanding performance: achieved 100% ORR, all patients achieved PR, and at the same time had better safety characteristics. This is the first clinical evidence that ADC combined with its parent antibody to enhance efficacy. This data supports continued patient enrollment and longer follow-up cycles in this study.

Extended follow-up data confirmed that JSKN003's PROC for multi-line treatment can bring stable and long-lasting anti-tumor benefits; long-lasting remission, prolonged PFS, and significant OS improvement can be achieved regardless of the patient's HER2 expression level. This advantage is closely related to the excellent tolerability of JSKN003. Currently, JSKN003 is undergoing phase III clinical research on PROC for the entire population, and it is expected to become a new treatment option that can prolong the survival of such refractory patients.

According to reports, JSKN003-003 is a multi-center, open-label, multi-cohort phase II clinical study aimed at evaluating the safety and efficacy of JSKN003 combination therapy in the first-line treatment of HER2+ unresectable locally advanced or metastatic GC/GEJ, or during perioperative treatment with resectable GC/GEJ.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.